Darobactine: eine neue Antibiotikaklasse in Entwicklung

Abstract The discovery pipeline for novel antibiotics runs dry, while antimicrobial resistances increase, causing 1.3 million deaths per year globally. Even in the European Economic Area with generally intact health care, more than 35,000 people die per year with numbers expected to rise. Especially...

Full description

Saved in:
Bibliographic Details
Published inBiospektrum Vol. 29; no. 5; pp. 539 - 541
Main Authors Seyfert, Carsten E., Porten, Christoph, Müller, Rolf
Format Journal Article
LanguageGerman
Published 01.09.2023
Online AccessGet full text

Cover

More Information
Summary:Abstract The discovery pipeline for novel antibiotics runs dry, while antimicrobial resistances increase, causing 1.3 million deaths per year globally. Even in the European Economic Area with generally intact health care, more than 35,000 people die per year with numbers expected to rise. Especially certain pathogenic Gram-negative bacteria are to blame. Optimized versions of the innovative natural product class of darobactins acting selectively at a novel target on the bacterial outer membrane may provide novel treatment options.
ISSN:0947-0867
1868-6249
DOI:10.1007/s12268-023-1988-6